Want to see ABOS full AI Analyst Report?
ABOS Stock Chart & Stats
$3.10
-$0.04(-1.84%)
At close: 4:00 PM EDT
$3.10
-$0.04(-1.84%)
Day’s Range― - ―
52-Week Range$1.21 - $3.60
Previous CloseN/A
Volume226.14K
Average Volume (3M)350.63K
Market Cap
$211.17M
Enterprise Value$114.36
Total Cash (Recent Filing)$110.20M
Total Debt (Recent Filing)$31.57M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Nov 16, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding72,317,280
10 Day Avg. Volume375,510
30 Day Avg. Volume350,626
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside93.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Phase II CatalystEarly target engagement and biomarker changes provide mechanistic support for sabirnetug and strengthen its evidence base. The Phase II readout should clarify efficacy, safety and biomarker durability.
Enhanced Brain Delivery PlatformThe EBD platform may address a major obstacle in neurodegenerative drug development: limited brain penetration. Higher exposure, retained oligomer selectivity and favorable preclinical safety could support a differentiated portfolio.
Near-term Liquidity And Cost ControlThe cash balance and controlled operating expenses provide resources to complete the current Phase II program and preserve flexibility around its major data milestone, while lower R&D spending moderates near-term cash consumption.
Bears Say
Pre-revenue Business ModelAcumen has no commercial product revenue, so funding depends on capital markets or future partnering rather than customer cash generation. This leaves the business exposed to financing conditions until a program reaches commercialization.
Persistent Cash Burn And Weaker Balance SheetSustained cash consumption, shrinking equity and rising debt reduce financial flexibility. The company may need additional capital to maintain development activity, creating dilution or funding risk before clinical programs generate returns.
Clinical And Development UncertaintyUnclear statistical handling of two active doses could complicate interpretation of the pivotal readout. Separately, the EBD candidates remain preclinical, with lead selection, clinical design and anemia-risk mitigation unresolved.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $1.21 and its highest was $3.60 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $211.17M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 73 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.359 by -$0.091.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 72,317,280 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.359. Following the earnings report the stock price went up 1.619%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Currently, no hedge funds are holding shares in ABOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acumen Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (93.55% Upside)
$6.00 (93.55% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $89.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
127.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
ABOS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful scientific and programmatic progress: a high-impact Phase II readout expected late 2026, strong Phase I target engagement, and a differentiated EBD program with compelling non-human primate brain exposures (up to 40x). Financially, the company is managing costs (R&D down versus prior year; G&A stable) but has a finite cash runway (approximately into early 2027) and reported a sizable quarterly net loss, which creates funding risk ahead of mid-2027 IND plans. Operational and design uncertainties (powering details for two-dose analysis, selection of EBD clinical lead, clinical start strategy) were noted but do not outweigh the near-term scientific catalysts and preclinical wins. Overall the tone is cautiously optimistic pending the upcoming ALTITUDE-AD topline.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$6.00
▲(93.55% Upside)
Technical Analysis
Ownership Overview
32.72% Insiders
5.71% Mutual Funds
45.01% Other Institutional Investors
11.16% Public Companies and
Individual Investors